Quality Assurance is an integral part of the drug development process and is crucial for GLP compliance. Porsolt has continually maintained GLP status since 2000, further validating the excellence of Porsolt’s services and the recognition of our global client base.
Mehdi Ellouze, Julien Valette and Sonia Rompion recently attended the European QA conference in Germany, as part of our ongoing efforts to maintain the high quality of preclinical drug development at Porsolt.
